In short
Clinical trials investigating Xylitol are studying how it performs in people with kidney disease and heart failure-related conditions. These studies look at safety, efficacy, and kidney dialysis outcomes, including whether Xylitol-containing trial products can support treatment goals in specific patient groups.
Key points
- Xylitol clinical trials in the source data are focused on kidney disease and heart failure-related care. One Phase 4 study looks at peritoneal ultrafiltration in people with congestive heart failure and measures death, hospital use, and worsening kidney or heart status. A Phase 2 study in end-stage kidney disease checks the safety of a PolyCore product that includes Xylitol, with close monitoring of lab tests and other health checks. A Phase 3 study in end-stage kidney disease compares Xylocore with standard glucose dialysis solutions and measures weekly Kt/V urea. Overall, the studies are authorized and mainly involve people with advanced kidney disease or heart failure.
Trial overview
The source data includes three authorised interventional trials that mention Xylitol as part of the study treatment. One trial is in Phase 4 for people with congestive heart failure, and two trials are in kidney disease, including Phase 2 and Phase 3 studies in end-stage kidney disease.
These studies are not general drug information studies; they are clinical research projects that test specific dialysis-related treatments and outcomes in defined patient groups.
Who is being studied
Two trials focus on end-stage kidney disease, which means very advanced kidney failure. These studies are aimed at people starting or receiving peritoneal dialysis, which is a kidney treatment that uses the lining of the belly to help remove waste and extra fluid.
One trial focuses on congestive heart failure and looks at whether peritoneal ultrafiltration can help prevent worsening of the condition. In simple terms, the study is asking whether the treatment can help patients avoid hospital stays, fluid problems, and kidney decline.
Study phases and designs
The heart failure study is a Phase 4 interventional trial with 84 planned participants. Phase 4 studies usually look at how a treatment performs in a more real-world setting after earlier testing.
The kidney disease safety study is a Phase 2 pilot trial with 28 planned participants. A pilot study is a small early study that helps researchers check whether a treatment appears safe and workable before larger research is done.
The kidney disease comparison study is a Phase 3 trial with 175 planned participants. This phase is used to compare a new treatment with standard care and see whether it performs at least as well as the current treatment.
What the trials measure
The Phase 4 heart failure study uses a composite endpoint, which means it combines several important results into one main outcome. The outcomes include patient death, hospitalisation for cardiovascular causes, the need for stronger diuretics or hemofiltration, a rise of at least 30% in loop diuretic dose, and worsening kidney function defined by very low eGFR.
The Phase 2 kidney study mainly focuses on safety, with repeated checks for adverse events, physical examination findings, vital signs, blood chemistry, blood counts, 24-hour urine output, 24-hour dialysate analysis, weekly Kt/V urea, and residual kidney function. These measures help researchers see whether the treatment is tolerated and whether kidney dialysis is working as expected.
The Phase 3 kidney study measures weekly Kt/V urea at several visits. This is a dialysis effectiveness measure that shows how well waste is being removed from the body.
Trial products and comparators
In the heart failure study, the intervention is listed as PolyCore used intraperitoneally, meaning it is placed into the abdominal cavity for treatment. The study summary says the goal is to see whether peritoneal ultrafiltration with PolyCore affects the main combined outcome of death or worsening condition.
In the Phase 2 kidney study, PolyCore is described as a ternary combination of Xylitol, L-Carnitine, and Polydextrin. The study summary says the main objective is to evaluate safety through ongoing monitoring of adverse events and clinical tests.
In the Phase 3 kidney study, Xylocore is described as a glucose-sparing experimental solution for peritoneal dialysis. The trial compares Xylocore with many standard glucose-based dialysis solutions and aims to show non-inferiority, which means it is not worse than the standard treatment for the main measure.
The source data lists several comparator products in the Phase 3 trial, including bicaVera, PHYSIONEAL, FIXIONEAL, balance, Dianeal PDG4, and equiBalance, all used intraperitoneally. This shows that the study is testing Xylitol-containing treatment against common dialysis solutions used in practice.
Key patient terms
Interventional trial means the researchers give a treatment and watch what happens, instead of only observing usual care.
Residual kidney function means the kidney still has some working ability, even if it is reduced.
Adverse events are unwanted health problems that happen during a study, and they are tracked closely for safety.
eGFR is a blood-test-based estimate of kidney filtering ability, and very low values can show serious kidney decline.
Hemofiltration is a blood-cleaning treatment used in severe illness when the body needs extra help removing fluid and waste.